Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Apotex Inc.
Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
May 26, 2026
Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
May 24, 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
May 22, 2026
Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180‑day CGT Exclusivity (Single‑Dose Vial), Complementing its Recent Approval of Generic Infuvite Adult Injection
May 20, 2026
Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
May 20, 2026
Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals
April 28, 2026
Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180‑Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
April 14, 2026
Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular
April 10, 2026
Apotex Strengthens Osteoporosis Care in Canada with Health Canada’s Approval of DENOZA™, a Denosumab Biosimilar
April 7, 2026
Apotex announces leadership changes
March 30, 2026
1
2
Next Page
→